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The brain contains a small but signiﬁcant amount of
glycogen, which has long been considered to play an
insigniﬁcant role in the brain. In this study, brain glycogen
metabolism was measured using 13C NMR spectroscopy
at 9.4 T. Brain glycogen metabolism was modulated by
hyperinsulinemia resulting in a net accumulation. The role
of glycogen in maintaining brain function is unknown;
one possibility is that it may serve as an endogenous
glucose reservoir to protect the brain against severe
hypoglycemia. To address this possibility, rats were sub-
jected to insulin-induced moderate hypoglycemia and
when the level of brain glucose approached zero, brain
glycogen content began to decrease gradually, demon-
strating utilization of this glucose reservoir. The brain
glycogen signal never became undetectable, however,
even during 2 hr of hypoglycemia. When plasma and
brain glucose concentrations were restored, glycogen
increased and the concentration exceeded the pre-
hypoglycemic level by several-fold. The data suggest
that brain glycogen can provide fuel for extended periods
of time when glucose supply is inadequate. Furthermore,
brain glycogen can rebound (super-compensate) after a
single episode of hypoglycemia. We postulate that brain
glycogen serves as an energy store during hypoglycemia
and that it may participate in the creation of reduced
physiological responses to hypoglycemia that are in-
volved in a symptom often observed in patients with
diabetes, hypoglycemia unawareness.
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A continuous supply of glucose from the blood is
considered essential for normal brain function. When a
sudden fall in plasma glucose occurs, the brain is protected
normally against hypoglycemia through a number of au-
tonomic counterregulatory responses, including the inhi-
bition of insulin secretion and the sequential release of
glucagon, epinephrine, norepinephrine, cortisol (ACTH)
and growth hormone (Gerich et al., 1991; Mitrakou et al.,
1991). Patients with Type 1 diabetes mellitus, however,
develop defective counterregulatory hormone responses
over time and glucose thresholds that elicit the counter-
regulatory responses are lowered by antecedent hypogly-
cemia. Eventually, patients with frequent hypoglycemia
may develop reduced physiological responses to hypogly-
cemia and lose their ability to detect and protect against
hypoglycemia until they develop frank neuroglycopenia
(insufﬁcient glucose supply to the brain) leading to hypo-
glycemia unawareness (Cryer, 1994).
How the brain adapts to recurrent abnormalities in
serum glucose levels is not clear. Over the past 20 years, it
has been suggested that glucose transport at the blood–
brain barrier is up- or downregulated during chronic
alterations of glycemia, and the alterations in glucose trans-
port might be a mechanism involved in impaired recog-
nition of hypoglycemia (Pelligrino et al., 1992; Boyle et
al., 1994; Kumagai et al., 1995; Amiel, 1998; Simpson et
al., 1999). These observations on the effect of hyper- and
hypoglycemia on glucose transport are conﬂicting, how-
ever, and it is therefore possible that the brain adapts to
alterations in glycemia through more than one mecha-
nism.
One alternative mechanism through which the brain
may adapt to hypoglycemia could include changes in brain
glycogen metabolism. Glycogen is an endogenous carbo-
hydrate store for energy metabolism in many tissues and
can be utilized increasingly when glucose supply is limited.
Brain glycogen has been suggested as a source of glucose
for the brain under extreme conditions (Clarke and
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Sokoloff, 1999). It has been considered generally, how-
ever, that brain glycogen stores are inadequate to meet all
basal metabolic demands based on reported cerebral gly-
cogen concentrations on the order of a few mol/g,
which can supply the glucose required for basal metabo-
lism for at most a few minutes during anoxia and aglyce-
mia (Clarke and Sokoloff, 1999). During anoxia, glycogen
is a less signiﬁcant source of energy (ATP synthesis) due to
the lower energetic yield of anaerobic metabolism (16-
fold), than during aglycemia. Furthermore, the deﬁcit in
glucose supply is expected to be gradual with a transition
from adequate to increasingly inadequate glucose trans-
port. Recent reports have suggested that brain glucose
transport across the brain has a rather low Km (Gruetter et
al., 1998b; Choi et al., 2001) consistent with that of the
major transporter isoform at the blood–brain barrier,
GLUT-1, which implies that a mismatch between glucose
supply and demand occurs during hypoglycemia only at
relatively low plasma glucose concentrations (Choi et al.,
2001) and that this mismatch is gradual. The role of brain
glycogen as a signiﬁcant glucose reservoir is supported
further by the observations that a limited reduction in the
concentration of glycogen occurred during hypoglycemia
(Kerr and Ghantus, 1936) and that endogenous cerebral
carbohydrate stores are used as substrates for metabolism in
hypoglycemia (Lewis et al., 1974; Norberg and Siesjo,
1976).
In most tissues, glycogen metabolism is sensitive to
alterations in plasma glucose and insulin concentrations
(van de Werve and Jeanrenaud, 1987; Richter et al.,
2001), which was observed in cell cultures (Dringen and
Hamprecht, 1992; Swanson and Choi, 1993) and some
evidence also supports this for the brain (Nelson et al.,
1968; Strang and Bachelard, 1971; Daniel et al., 1977). In
addition, glycogen has been shown to replete to levels
higher than the predepletion levels in tissues such as mus-
cle, liver, and heart when ample substrate and hormones
are present during recovery. This rebound in glycogen
content has been termed “super-compensation” (Poland
and Trauner, 1973; Gorski et al., 1976). Super-
compensation of brain glycogen has also been reported
after an ischemic episode (Folbergrova et al., 1996). This
suggests that super-compensation is a general feature of
glycogen metabolism.
We demonstrated recently (Choi et al., 1999, 2000)
that brain glycogen metabolism can be measured in vivo
using direct 13C nuclear magnetic resonance (NMR) de-
tection in conjunction with infusion of 13C-labeled glu-
cose. We employed these methods to test the hypothesis
that brain glycogen serves as a source of energy during
periods of hypoglycemia. We sought to determine: 1)
whether brain glycogen metabolism can be affected by
changes in plasma insulin concentrations; 2) whether brain
glycogen is a signiﬁcant source of glucosyl units during
insulin-induced hypoglycemia; and 3) whether brain gly-
cogen concentrations can super-compensate after a single
episode of hypoglycemia.
MATERIALS AND METHODS
Animals
The study was approved and conducted according to
guidelines for the care and use of laboratory animals at the
University of Minnesota. Male Sprague-Dawley rats (258 8 g,
mean  SE, n  20) were studied after fasting overnight with
free access to water. Animals were anesthetized using 2% isoﬂu-
rane (Marsam Pharmaceuticals, Cherry Hill, NJ) in a 1:1 mix-
ture of nitrous oxide (N2O) and oxygen (O2) gases for surgery.
The animals were then intubated and ventilated with a pressure-
driven ventilator (Kent Scientiﬁc, Litchﬁeld, CT). Catheters
were inserted into both femoral arteries for blood gases, glucose
analyses, and monitoring of arterial blood pressure. Two addi-
tional catheters were inserted into both femoral veins for intra-
venous infusion of -chloralose, glucose, insulin and somatosta-
tin. Arterial blood pressure, respiratory rate and pattern were
monitored continuously with a multi-trace recorder (Acq-
Knowledge, Biopak, CA). End tidal CO2 also was monitored
continuously during surgery and experiments with a capnometer
(SC-300; BCI International, Waukesha, WI).
Immediately after surgery, anesthesia was switched to
-chloralose, which was administered as follows: 40 min after a
40 mg/kg bolus injection, a continuous i.v. infusion was started
(24–26.7 mg/kg/hr) as in our previous study (Choi et al., 2001).
The animals were secured using a home-built Delrin holder
with a bite bar and two ear inserts to provide a ﬁxed position of
the skull. The animal was then placed in an acrylic holder
attached to an insert in the gradient coil, which ensured stability
of the experimental setup for extended measuring times. Body
temperature was maintained at 37.0 0.5°C with a warm water
circulation system based on a feedback obtained from a rectal
temperature probe (Cole Palmer, Vernon Hills, IL).
The study was conducted in two groups of animals. In the
ﬁrst group of animals (n  12), the effect of insulin on brain
glycogen metabolism was assessed. In these animals, the prepa-
ration was identical to that described previously (Choi et al.,
1999, 2001) and 99%-enriched [1-13C] D-glucose (20% wt/vol
solution, Isotec Inc., Miamisburg, OH) was infused into the left
femoral vein according to an infusion protocol described previ-
ously (Choi et al., 1999). Glucose concentrations in the brain
were measured continuously by 13C NMR and maintained at
approximately 3 mol/g for 4 hr by adjusting the rate of the
glucose infusion accordingly. While infusing glucose, insulin
was infused at 6 IU/kg/hr to induce hyperinsulinemia in six
animals; in the other six animals, somatostatin was infused at
0.7–0.8 g/kg/min to suppress pancreatic  cell function and to
minimize plasma insulin concentrations (Rossetti et al., 1993).
The second group of animals (n 8) was used to assess the
effect of hypoglycemia on brain glycogen metabolism. These
animals were treated initially in the same manner as animals in
Group I, except that no exogenous hormone was administered.
The brain glucose concentration was maintained at 3 mol/g
before and after hypoglycemia in all experiments. To induce
hypoglycemia, insulin (24–40 IU/kg, Humulin R, Eli Lilly &
Co., Indianapolis, IN) was administrated intravenously and the
[1-13C] glucose infusion rate was reduced to 0.2 mg/min. The
degree and duration of hypoglycemia (below 2 mM plasma
glucose concentration for approximately 2 hr measured in a
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nearby glucose analyzer every 10–15 min) were controlled by
concomitant measurements of brain and plasma glucose levels,
and designed to avoid any extensive damage to brain tissue. This
was conﬁrmed by stable amino acid concentrations during hy-
poglycemia using localized 1H NMR spectroscopy (n  3).
Arterial blood was withdrawn through Teﬂon tubing lines
(Spectrum Chromatography, Houston, TX) for blood gas anal-
ysis. Physiological parameters were maintained within normal
range at pCO2 39.9 1.6 mm Hg, pO2 186.4 15.1 mm
Hg and arterial pH  7.4  0.02.
NMR Methods
All experiments were carried out on a 9.4-T, 31-cm
horizontal-bore magnet (Magnex Scientiﬁc, UK), interfaced to
a Varian INOVA console (Palo Alto, CA). An actively shielded
gradient coil (Magnex Scientiﬁc, Abingdon, UK) with an
11-cm inner diameter was used and a home-built quadrature 1H
surface RF coil (14-mm diameter) and a linear polarized three-
turn 13C coil (12-mm diameter) were used as a transceiver for
1H NMR and 13C NMR as described previously (Adriany and
Gruetter, 1997). A 99% 13C-enriched formic acid sphere was
located at the center of the 13C coil as an external reference and
the coil was placed on the animal’s head (Choi et al., 2000).
Automated localized shimming with a fully adiabatic version of
FAST(EST)MAP was used (Gruetter and Tkac, 2000). The full
width at half-maximum of the in vivo water signal was about 20
Hz in a nominal 510 l volume (8.5  6  10 mm3). The
volume of interest (VOI) was placed in the rat brain to avoid
signal contamination from extra-cerebral tissues as demonstrated
previously (Choi et al., 1999, 2000). The efﬁciency of three-
dimensional localization was veriﬁed continuously from the
absence of the 30.5 ppm natural abundance lipid signal in spectra
optimized for the amino acid region (20–40 ppm) acquired in
an interleaved fashion with spectra optimized for the detection
of glycogen and glucose C1 signals, as the lipid signals are not
detectable in the normal brain.
Quantiﬁcation of NMR Signals
The 13C NMR signals of brain glycogen and glucose were
quantiﬁed using the external reference method (Gruetter et al.,
1998a; Choi et al., 1999). In brief, in vivo 13C NMR signals of
glycogen and glucose were quantiﬁed by comparison with the
measurements of phantoms containing 400 mM natural abun-
dance oyster glycogen and 0.9 mM of 99%-enriched [1-13C]
D-glucose after correction for the effects of loading and nuclear
Overhauser effect on the NMR signals.
In addition, 1H NMR spectra were acquired in three
animals for quantiﬁcation of brain glucose and amino acid
concentrations such as NAA, glutamate, glutamine, and aspar-
tate in conjunction with unlabeled glucose infusion. Glucose
quantiﬁcation was carried out by frequency domain analysis
with LCModel (Pfeuffer et al., 1999) from a 150 l volume in
the brain. A STEAM sequence was used with 2-msec echo time,
5-sec repetition time, and 20 msec mixing time (Tkac et al.,
1999).
RESULTS
The experiments carried out in the ﬁrst group ad-
dressed the question of whether insulin alone has an effect on
brain glycogen metabolism. In these animals, the amount of
13C label incorporated into glycogen was measured after
4 hr of 13C glucose infusion with either intravenous
infusion of insulin (6 IU/kg/hr) or somatostatin (0.7–0.8
g/kg/min). Somatostatin effectively suppresses endoge-
nous insulin secretion, which was evident in our experi-
ments by the greatly reduced glucose infusion rate
required to maintain constant plasma glucose concen-
trations. Plasma glucose concentrations were 10.3 
1.4 mM (mean  SD, n  6) for the insulin group and
11.7  2.1 mM (mean  SD, n  6) for the soma-
tostatin group, resulting in brain glucose concentrations
of 3.4  0.5 mol/g and 3.8  0.4 mol/g, respec-
tively. After 4 hr of 13C-labeled glucose infusion, the
concentration of [1-13C] glycogen was 5.8  0.4
mol/g when infusing insulin, whereas the glycogen
C1 concentration was only 2.1  0.6 mol/g (n  6,
P  0.0001) when infusing somatostatin alone (Fig. 1).
In the second group of animals, the effect of hypo-
glycemia on brain glycogen metabolism was assessed. In
these studies, brain glucose was clamped at 3.2  0.2
mol/g (mean SE, n 8) for at least 4 hr while infusing
99% enriched [1-13C] glucose. Clamping glucose resulted
in very stable brain glucose signals after an initial short
equilibration period (Fig. 2A, top stack plot), consistent
with a stable plasma glucose concentration. The initial
labeling of glycogen C1 from 13C-labeled glucose led to
an appreciable glycogen C1 signal (Fig. 2A, bottom stack
plot), corresponding to a concentration of [1-13C] glyco-
gen of 3.6  0.2 mol/g (mean  SE). After a primed-
continuous administration of 24–40 IU/kg of insulin (the
start of which is indicated by the arrow in Fig. 2A) and a
drastic reduction in the [1-13C] glucose infusion rate to 0.2
mg/min, the brain glucose concentration decreased as a
Fig. 1. Effect of insulin on brain glycogen metabolism. Increased 13C
label incorporation into brain glycogen was observed during insulin
infusion (left, n  6) compared to the somatostatin (SRIF) infusion
(right, n 6) (**P 0.001). In both groups, glucose concentrations in
the brain and plasma were maintained constant. Error bars indicate
standard deviation. Measurements were carried out after four hours of
intravenous infusion of [1-13C] glucose, while administering insulin (6
IU/kg/hr) in one group and somatostatin (0.7–0.8 g/kg/min) in the
other.
Brain Glycogen Repletion After Hypoglycemia 27
result of the ensuing hypoglycemia. The plasma glucose
concentration was below 2 mM for 2 hr.
During hypoglycemia, the glycogen C1 signal de-
creased discernibly, presumably due to decreased synthase
activity and increased phosphorylase activity. The decrease
in glycogen C1 started when brain glucose concentration
was 0.1  0.1 mol/g. Once the brain glucose concen-
tration was close to zero, brain glycogen C1 decreased
with a rate of 	64  8%/hr (mean  SE, n  8) of the
pre-hypoglycemic [1-13C] glycogen signal. Even after 2 hr
of hypoglycemia, the brain glycogen C1 signal was de-
tectable and we were unable to note complete elimination
(Fig. 2).
Hypoglycemia was terminated by stopping the insu-
lin infusion and increasing the rate of the [1-13C] glucose
infusion to restore the plasma glucose concentration to the
pre-hypoglycemia level, resulting in a 3.3  0.1 mol/g
brain glucose concentration. The brain glycogen C1 signal
started to increase immediately at an initial rate of 1.9 
0.4 mol/g/hr (mean  SE, n  8). Glycogen C1 con-
tinued to rise and reached 6.8 0.7 mol/g (mean SE,
n  7) 4 hr after glucose supply had been restored, and
amounted to a level that was 153  30% above basal (P 
0.01, n  5, Fig. 3B) 7 hr after ending hypoglycemia. In
several cases, glycogen concentrations were more than 10
mol/g and continued to rise (Fig. 2B).
Figure 3A shows representative spectra of the glyco-
gen and glucose region before (top), during (middle), and
after hypoglycemia (bottom) of the rat brain. Each spec-
trum was acquired 4 hr after the start of 13C glucose
infusion (top), 2 hr after the start of insulin infusion for
hypoglycemia (middle) and 4 hr after the restart of 13C
glucose infusion to restore the plasma glucose concentra-
tion to the pre-hypoglycemia level (bottom), respectively.
During hypoglycemia, the glycogen C1 signal was de-
creased, but clearly visible at 100.6 ppm, whereas glucose
signals were not detectable. After hypoglycemia, a distinc-
tive increase of the glycogen C1 signal was observed
whereas the intensity of glucose signals remained the same
as during the pre-hypoglycemic period (Fig. 3A, bottom).
Sequentially-acquired localized 1H NMR spectros-
copy was used to assess whether any major changes in
amino acid concentrations or energy phosphates (PCr)
occurred during the speciﬁc hypoglycemic protocol used
in this study. These preliminary measurements indicated
that the concentrations of creatine, phosphocreatine, and
amino acids such as aspartate and glutamate did not change
by more than 10%.
DISCUSSION
This study demonstrated that brain glycogen metab-
olism varied with changes in plasma insulin. An episode of
insulin-induced hypoglycemia led to a depletion of brain
glycogen whereas restoration of glycemia led to super-
compensation in brain glycogen content. These observa-
tions suggest that brain glycogen may serve as a source of
glucosyl units during insulin-induced hypoglycemia and
suggest that brain glycogen may play a more important
role in metabolism than was assumed previously.
Fig. 2. Time-resolved changes of [1-13C] cerebral glycogen and glu-
cose signals during insulin-induced hypoglycemia. A: A horizontal
stack plot of three-dimensional localized 13C NMR spectra of the rat
brain showing the glycogen C1 signals (bottom) and the -glucose C1
signals (top trace). Each spectrum corresponds to 12 min of data
accumulation, and all spectra are from the same animal (LB  20 Hz).
The start of insulin infusion is indicated by the arrow, which was ended
when the 13C glucose concentration was restored. Hypoglycemia,
indicated by the bracket, was the time during which the brain glucose
signal was within the noise. B: Time-course of the quantiﬁed glycogen
C1 and glucose C1 signals. Data are from the same animal as in (A).
During hypoglycemia, plasma glucose concentration was below 2 mM
for 2 hr and brain glucose concentration was below 0.1 mol/g as
indicated by the horizontal dotted line. The vertical dashed line indi-
cates the start of glycogenolysis during hypoglycemia, which coincided
with the time point where brain glucose approached zero.
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Assessment of Insulin Effects on Brain Glycogen
In the insulin-treated group, the amount of 13C label
incorporated into glycogen was three-fold higher than in
the somatostatin-treated group, where insulin secretion
was suppressed (Fig. 1). Because the plasma and brain
glucose concentrations in both groups were very similar,
this result suggests that plasma insulin alone has a strong
effect on brain glycogen metabolism. The amount of label
in glycogen in the group receiving insulin exceeded the
normal brain glycogen concentration, which demonstrates
an increase in brain glycogen content. It has been reported
previously that brain glycogen increases 1 hr after insulin
administration (Daniel et al., 1977). Our results were
obtained at a much lower plasma glucose concentration
than the studies by Daniel et al. (1977), thus supporting
the notion that brain glycogen provides an aspect of in
vivo cerebral carbohydrate metabolism that is sensitive to
changes in plasma insulin.
Effect of Hypoglycemia on Brain Glycogen
Metabolism
During insulin-induced hypoglycemia, degradation
of brain [1-13C] glycogen started when brain glucose
concentrations were 0.1  0.1 mol/g, which is close to
the Km of hexokinase. This is also the point where we
observed that glucose transport became rate limiting for
metabolism and when CBF was increased acutely (Choi et
al., 2001). Clearly, the brain glycogen C1 signal remained
observable after 2 hr of hypoglycemia (Fig. 2). The inabil-
ity to achieve complete depletion of [1-13C] glycogen
during prolonged periods of hypoglycemia demonstrates
that the brain glycogen pool can survive extended periods
of hypoglycemia, suggesting that glycogen serves as a
signiﬁcant carbohydrate reservoir during mild hypoglyce-
mia and can account for a partial deﬁcit in glucose supply.
In this context, it is interesting to note that brain glucose
transport seems to have a low Km on the order of 1–3 mM
(Gruetter et al., 1998b; Choi et al., 2001; de Graaf et al.,
2001; Seaquist et al., 2001), consistent with that of
GLUT-1, the ubiquitous glucose transporter at the blood–
brain barrier. Such a low Km implies that substantial trans-
port of glucose occurs during hypoglycemia, even when
brain glucose concentrations are zero.
Because the average plasma glucose concentration
was estimated at 1.5 mM during the hypoglycemic period
in our study, the kinetic constants of glucose transport
measured for the rat anesthetized under identical condi-
tions as in the present study (Choi et al., 2001) imply a
relative glucose consumption deﬁcit of approximately
15%. The average degradation rate of 64%/hr of the
estimated pre-hypoglycemic concentration amounts to a
glycogenolytic ﬂux of 0.038  0.005 mol/g/min. This
glycogenolytic rate is on the order of 13–15% of the
reported basal glucose consumption rates for the
Fig. 3. Super-compensation of brain glycogen concentration. A: A
stack plot of glycogen and glucose signals measured before, during and
after hypoglycemia. The three-dimensional localized 13C NMR spectra
show the signal changes of glycogen and glucose before (top), during
(middle) and after (bottom) hypoglycemic periods. The corresponding
resonances of glycogen and glucose in the brain were at 100.6 ppm
(glycogen C1), 92.96 ppm (-glucose C1) and 96.80 ppm (-glucose
C1), respectively. Each spectrum corresponds to 10 min of data accu-
mulation (LB  20 Hz). B: Brain glycogen C1 concentrations mea-
sured before, during and after hypoglycemia. Repletion of brain gly-
cogen concentrations after hypoglycemia clearly demonstrates excess
storage. The glycogen concentration increased by 87  10% (n  7)
4 hr after and by 153  30% (n  5) 7 hr after ending hypoglycemia
(*P  0.01). The dashed line indicates the normal euglycemic brain
glycogen concentration (Siegel and Agranoff, 1999; Gip et al., 2002;
Kong et al., 2002). Error bars indicate standard error.
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-chloralose anesthetized rat (Shulman et al., 1999; Nakao
et al., 2001), suggesting that in our experiments, glyco-
genolysis accounted for a substantial fraction or even all of
the glucose supply deﬁcit. Therefore, brain glycogen is
likely to play a signiﬁcant role during hypoglycemia. One
possible neuroprotective mechanism of glycogen is to
provide ATP to allow continuous uptake of excitotoxic
glutamate from the synaptic cleft and to provide lactate as
a fuel for neurons (Magistretti and Pellerin, 1996).
Seven hours after resuming the glucose infusion to
restore glycemia, 13C-labeled brain glycogen concentra-
tions approached 10 mol/g (Fig. 3B), which is approx-
imately three times the normal brain glycogen concentra-
tion of 3.3 mol/g (Siegel and Agranoff, 1999). Thus our
study demonstrates clearly that the brain glycogen levels
can exceed the pre-hypoglycemic level after hypoglyce-
mia, as also can be seen from the substantially increased
glycogen C1 signal (Fig. 3A). Our results, therefore, for
the ﬁrst time provide direct experimental in vivo data
supporting the hypothesis that super-compensation of gly-
cogen in the brain occurs after a single episode of insulin-
induced hypoglycemia. Because this result is consistent
with the observation that a single episode of hypoglycemia
can lead to blunting of the counter-regulatory hormones
during subsequent hypoglycemia (hypoglycemia unaware-
ness) (Cryer, 1994; Davis et al., 1997; Fanelli et al., 1998),
it is possible that glycogen metabolism may be involved in
the development of the hypoglycemia unawareness syn-
drome, as increased glycogen content leads to increased
neuronal protection against neuroglycopenia (Dringen
and Hamprecht, 1992; Swanson and Choi, 1993).
Because the study relied on measuring 13C-labeled
glucose and observing 13C incorporation into brain gly-
cogen, it is possible that 13C label cycling (turnover) could
confound our measurements. Although this is a distinct
possibility, label exchange per se is unlikely to alter the
qualitative nature of the observations and the conclusions
of this study. To assess whether turnover of the 13C-
labeled glycogen pool may alter the conclusions of the
present study, we veriﬁed the following points.
First, in Group I, labeling of the brain glucose oc-
curred on a similar time scale in the animals receiving
insulin compared to those receiving somatostatin. Because
these experiments were carried out under conditions of
acutely raised glucose, resulting in mild hyperglycemia,
the isotopic enrichment of brain glucose rapidly ap-
proached that of the infusate (99%), which has been our
consistent experience in humans (Gruetter et al., 1998a,
2001) and in rats (Choi et al., 2001). Furthermore, because
total glycogen is given by the sum of labeled glycogen
(denoted by 13Glyc1) and unlabeled glycogen (
12Glyc1),
i.e., [Glyc]  13Glyc1 

12Glyc1, it is obvious that the
relationship 13Glyc1(t)  [Glyc](t) always holds. Hence,
the total glycogen concentration in the insulin-treated
group [Glyc]  13Glyc1(t)  5.8 mol/g. Therefore, it is
obvious that net glycogen synthesis must have occurred,
because the amount of quantiﬁed 13C label is twofold
higher than the total brain glycogen, [Glyc]0, we observed
in rats without exogenous insulin infusion (Choi and
Gruetter, 2003) and what has been reported as the normal
brain glycogen concentration (Siegel and Agranoff, 1999;
Gip et al., 2002; Kong et al., 2002). This implies that the
total glycogen concentration [Glyc](t) in the insulin-
treated group was higher than normal. This is consistent
with our earlier study, where we explicitly measured label
turnover during glucose infusion, which most likely re-
sulted in additional insulin secretion (Choi et al., 1999).
Because the insulin-treated animals in Group I of this
study had the highest amount of label incorporation (5.8
mol/g), we propose that serum insulin plays an impor-
tant role in the regulation of brain glycogen metabolism.
There is plausible cause for such an action because insulin
has been shown to cross the blood–brain barrier and can
act through numerous receptors found in the brain as well
as at the blood–brain barrier (Banks et al., 1997).
Second, during hypoglycemia in Group II, it is pos-
sible that unlabeled substrate could enter the glycogen
pool, thereby leading to an overestimate of the rate of
glycogenolysis; however, the [1-13C] glucose infusion
continued at a reduced rate during hypoglycemia. In ad-
dition, it is expected that the ﬂux through glycogen syn-
thase is reduced during hypoglycemia and much lower
than under normal conditions. The observed rate of gly-
cogen degradation, however, was several-fold higher (2.3
mol/g/hr) than the normal turnover rate of glycogen
(0.5 mol/g/hr) (Choi et al., 1999). Thus, we conclude
that label exchange during hypoglycemia is an unlikely
explanation of the observed rapid decline in 13C-labeled
glycogen.
Finally, the 13C-labeled brain glycogen concentra-
tion observed 7 hr after hypoglycemia was increased,
which can, in principle, be due to replacing the unlabeled
glucosyl units with labeled glucosyl units (turnover). Label
turnover alone, however, cannot account for a [1-13C]
glycogen concentration that was several-fold higher than
the normal brain glycogen concentration (see above).
Therefore, we conclude that although turnover can per-
haps affect some of the measurements quantitatively, the
conclusions drawn from the studies reported herein cannot
be explained by turnover alone and hence, net synthesis
must have occurred. This is supported further by an early
report that brain glycogen may have rebounded after
severe hypoglycemia and ischemia in the awake rat brain
(Folbergrova et al., 1996). That study did not measure the
rate of glycogen depletion during hypoglycemia, however,
and thus did not establish further the importance of brain
glycogen as a potential store of glucose during the more
moderate hypoglycemia studied here.
In addition to glycogen, amino acids and lactate can
serve as fuels during insulin-induced hypoglycemia. Our
estimation that overall ATP production due to glycogen-
olysis covers much of the glucose deﬁcit during hypogly-
cemia further implies that amino acids are not a major
component of fuel usage during moderate hypoglycemia,
which is consistent with the observation that amino acid
concentrations were rather constant (data not shown).
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This observation was also consistent with the observation
that amino acid depletion occurs when PCr is decreasing,
which was not observed in the present study and has been
reported at plasma glucose concentrations of approxi-
mately 1 mM and below in the awake rat, substantially
lower than those maintained during our experiments
(Agardh et al., 1978). Our levels of plasma glucose during
hypoglycemia were typically higher, corresponding to
more moderate hypoglycemia. Furthermore, even though
light anesthesia was used in the present study, a reduction
of the cerebral glucose metabolic rate compared to these
early studies is likely and thus the point at which PCr is
depleted may have been shifted to below 1mM. Con-
versely, it is likely that brain glycogen would become
depleted in the awake animal at a much higher plasma
glucose concentration, which further underscores the im-
portance of brain glycogen as a neuroprotective glucose
store.
The observations in our study also shed light on the
proposed use of lactate as neuronal metabolic fuel. During
hypoglycemia, when glucose transport across the blood–
brain barrier becomes rate limiting for cellular metabolism,
brain glycogen, found exclusively in astrocytes in the adult
brain, can provide a substantial fraction of the fuel deﬁcit
for extended periods. Because most of the oxidative car-
bohydrate metabolism in vivo is in neurons (Gruetter et
al., 2001), it is likely that glycogen-derived fuel is metab-
olized to pyruvate. Pyruvate, a substrate that is extensively
metabolized by neurons, can easily be converted to lactate
in glia. This supports the postulation that glial-derived
lactate is a signiﬁcant source of fuel for neurons under
stimulated conditions (Dringen et al., 1993; Magistretti et
al., 1993; Alves et al., 1995; Grifﬁn et al., 1999). Alterna-
tively, astrocytic glycogen may provide fuel to allow con-
tinued glutamate uptake into astrocytes and conversion to
glutamine to reduce hypoglycemic brain injury through
reduced glutamate excitotoxicity. Therefore, an under-
standing of the regulation of brain glycogen metabolism is
key in providing insights into brain energy metabolism
with respect to the neuronal–astrocytic metabolic rela-
tionship.
CONCLUSIONS
We conclude that acute hyperinsulinemia has a
strong effect on brain glycogen metabolism leading to net
glycogen synthesis. From the slow rate of glycogen deple-
tion and the apparent inability of prolonged hypoglycemia
to deplete glycogen completely, we conclude that brain
glycogen can provide glucosyl units for extended periods
during moderate hypoglycemia, and that glycogenolysis
can account for the majority of the glucose deﬁcit. The
evidence in this study supports the hypothesis that post-
hypoglycemic can exceed pre-hypoglycemic glycogen
concentrations several-fold, providing excessive glucosyl
storage that potentially may interfere with the ability of
glucose-sensing and glucose-responsive neurons to recog-
nize hypoglycemia during subsequent hypoglycemic epi-
sodes. Therefore, we postulate that brain glycogen may
play a signiﬁcant neuroprotective role in vivo and that
glycogen metabolism may be involved in the pathogenesis
of hypoglycemia unawareness after hypoglycemic episodes
observed in patients with diabetes mellitus.
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